<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000559139"><TermName>indium In 111 CHX-A DTPA trastuzumab</TermName><TermPronunciation>(IN-dee-um … tras-TOO-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the imaging of breast cancer and some other types of cancer. It is made by attaching a radioactive substance called indium 111 to the monoclonal antibody trastuzumab (Herceptin). Trastuzumab binds to the human growth factor receptor 2 (HER2/neu) on some breast cancer cells and on several other types of cancer cells. Indium In 111 CHX-A DTPA trastuzumab is a type of radioimmunoconjugate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720441" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;indium In 111 CHX-A DTPA trastuzumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720440" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;indio 111 CHX-A DTPA trastuzumab&quot;" language="es" id="_4"/><SpanishTermName>indio 111 CHX-A DTPA trastuzumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para la formación de imágenes del cáncer de mama y algunos otros tipos de cáncer. Se elabora mediante la unión de una sustancia radiactiva llamada indio 111 (In 111) al anticuerpo monoclonal trastuzumab (Herceptin). El trastuzumab se une al receptor del factor de crecimiento humano 2 (HER2/neu) de algunas células de cáncer de mama y de varios otros tipos de células cancerosas. El indio 111 trastuzumab CHX-A DTPA es un tipo de radioimmunoconjugado.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-03-31</DateFirstPublished></GlossaryTerm>
